<p>The intravenous and oral forms of valproic acid are expected to produce the same AUC, Cmax, and Cmin at steady-state.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Official drug label" href="#label-reference">Label</a></sup> The oral delayed-release tablet formulation has a Tmax of 4 hours. Differences in absorption rate are expected from other formulations but are not considered to be clinically important in the context of chronic therapy beyond impacting frequency of dosing. Differences in absorption may create earlier Tmax or higher Cmax values on initiation of therapy and may be affected differently by meals.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Depakene FDA Label (2019)" href="#reference-L6196">30</a></sup> The extended release tablet formulation had Tmax increase from 4 hours to 8 hours when taken with food. In comparison, the sprinkle capsule formulation had Tmax increase from 3.3 hours to 4.8 hours. Bioavailability is reported to be approximately 90% with all oral formulations with enteric-coated forms possibly reaching 100%.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Zaccara G, Messori A, Moroni F: Clinical pharmacokinetics of valproic acid--1988. Clin Pharmacokinet. 1988 Dec;15(6):367-89. doi: 10.2165/00003088-198815060-00002. (PubMed ID 3149565)" href="#reference-A178066">27</a></sup></p>